propranolol has been researched along with Fetal Growth Retardation in 10 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Fetal Growth Retardation: Failure of a FETUS to attain expected GROWTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neonatal hyperthyroidism is usually a self-limited condition frequently associated with transplacental passage of thyroid stimulating antibodies secondary to maternal autoimmune disorders." | 1.40 | [Heart failure as early manifestation of neonatal hyperthyroidism. Case report]. ( Alvarado S, JL; Fernández V, ZA, 2014) |
| "Fetal cardiac arrhythmias are usually first suspected on the basis of auscultatory findings during routine examination in pregnancy." | 1.27 | Treatment of fetal cardiac arrhythmias. ( Stewart, PA; Wladimiroff, JW, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, L | 1 |
| Ng, A | 1 |
| Chen, W | 1 |
| Spencer, HT | 1 |
| Lee, MS | 1 |
| Bisschop, PH | 1 |
| van Trotsenburg, AS | 1 |
| Alvarado S, JL | 1 |
| Fernández V, ZA | 1 |
| Pombo Arias, M | 1 |
| Redmond, GP | 2 |
| Llanos, AJ | 1 |
| Green, JR | 1 |
| Creasy, RK | 1 |
| Rudolph, AM | 1 |
| Smith, C | 1 |
| Thomsett, M | 1 |
| Choong, C | 1 |
| Rodda, C | 1 |
| McIntyre, HD | 1 |
| Cotterill, AM | 1 |
| Pruyn, SC | 1 |
| Phelan, JP | 1 |
| Buchanan, GC | 1 |
| Wladimiroff, JW | 1 |
| Stewart, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients: a Double-blind Randomized Controlled Trial[NCT03348683] | Phase 2 | 240 participants (Actual) | Interventional | 2017-12-11 | Completed | ||
| Propranolol for Prolonged Labor: A Randomized Controlled Trial (PRO-Labor Trial)[NCT04741698] | Phase 1 | 80 participants (Actual) | Interventional | 2021-07-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Time of latent labor defined as <6cm of cervical dilation. (NCT03348683)
Timeframe: average of 24 hours
| Intervention | hours (Mean) |
|---|---|
| Propranolol | 11.0 |
| Placebo | 11.2 |
Count of fetus with fetal bradycardia (<110bpm for >10 minutes within 30 minutes of study drug administration) (NCT03348683)
Timeframe: 30 minutes from drug administration
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 1 |
| Placebo | 0 |
Count of fetus with fetal heart rate decelerations within 30 minutes of study drug administration (NCT03348683)
Timeframe: 30 minutes from drug administration
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 15 |
| Placebo | 13 |
"Neonatal outcome - Number of neonates with hypoglycemia (blood glucose <50).~This population includes only the neonates who had heelsticks to check their blood glucose, which is not a universal practice and was not required by the protocol or IRB. The neonates included were those who met the nursery's risk-based protocol to check blood glucose after birth (ex: infants of diabetic mothers, fetal growth restriction, macrosomia, or symptoms suggestive of hypoglycemia)" (NCT03348683)
Timeframe: Day 1
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 11 |
| Placebo | 8 |
"Composite neonatal outcome score was for any of the following morbidity: Neonatal Intensive Care Unit (NICU) admission, respiratory support (CPAP, nasal cannula, intubation), culture proven sepsis, radiographically proven intracranial hemorrhage, necrotizing enterocolitis, hypoglycemia (for those infants who had sugar checked), and neonatal death.~The composite score was computed as a score of 1 for any indication of neonatal morbidity - neonates who experienced at least one morbidity and the components are given equal weights. Patients who had no evidence of the predefined neonatal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1." (NCT03348683)
Timeframe: Day 1
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 21 |
| Placebo | 28 |
"Composite maternal morbidity score consists of a count of postpartum hemorrhage, transfusion, hysterectomy, placental abruption, chorioamnionitis, shoulder dystocia, episiotomy, higher order laceration, and ICU admission.~The composite score was computed as a score of 1 for any indication of maternal morbidity, that is the participant experienced at least one maternal morbidity, and the components are given equal weights. Participants who had no evidence of the predefined maternal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1." (NCT03348683)
Timeframe: average of 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 35 |
| Placebo | 49 |
Greater than 500cc of blood expelled during a vaginal delivery or greater than 1000cc of blood expelled during a cesarean section (NCT03348683)
Timeframe: 30 minutes from drug administration
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 15 |
| Placebo | 26 |
The time of induction (based on time of foley balloon placement for cervical ripening or misoprostol administration) to the time of delivery of the infant. (NCT03348683)
Timeframe: average of 24 hours
| Intervention | hours (Mean) |
|---|---|
| Propranolol | 13.8 |
| Placebo | 14.3 |
Number of various mode of delivery - count of Vaginal delivery, vacuum assisted vaginal delivery, forceps assisted vaginal delivery, cesarean section (NCT03348683)
Timeframe: average of 24 hours
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Spontaneous vaginal delivery | Vacuum assisted vaginal delivery | Forceps assisted vaginal delivery | Cesarean section | |
| Placebo | 61 | 10 | 8 | 40 |
| Propranolol | 64 | 3 | 8 | 46 |
2 reviews available for propranolol and Fetal Growth Retardation
| Article | Year |
|---|---|
[Progress in the study of growth retardation].
Topics: Adolescent; Age Determination by Skeleton; Child; Child, Preschool; Chromosome Aberrations; Chromoso | 1984 |
Effect of drugs on intrauterine growth.
Topics: Abnormalities, Drug-Induced; Animals; Ethanol; Female; Fetal Growth Retardation; Fetus; Growth; Huma | 1979 |
8 other studies available for propranolol and Fetal Growth Retardation
| Article | Year |
|---|---|
Beta-blocker subtypes and risk of low birth weight in newborns.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Birth Weight; California; Fem | 2018 |
Images in clinical medicine. Neonatal thyrotoxicosis.
Topics: Adult; Apgar Score; Eyelids; Female; Fetal Growth Retardation; Graves Disease; Heart Rate, Fetal; Hu | 2014 |
[Heart failure as early manifestation of neonatal hyperthyroidism. Case report].
Topics: Adrenergic beta-Antagonists; Antithyroid Agents; Fetal Growth Retardation; Heart Failure; Humans; Hy | 2014 |
Propranolol and fetal growth retardation.
Topics: Animals; Female; Fetal Growth Retardation; Humans; Pregnancy; Propranolol; Prospective Studies; Spec | 1982 |
Increased heart rate response to parasympathetic and beta adrenergic blockade in growth-retarded fetal lambs.
Topics: Animals; Atropine; Blood Gas Analysis; Blood Pressure; Body Weight; Female; Fetal Growth Retardation | 1980 |
Congenital thyrotoxicosis in premature infants.
Topics: Antithyroid Agents; Autoantibodies; Carbimazole; Female; Fetal Blood; Fetal Growth Retardation; Grav | 2001 |
Long-term propranolol therapy in pregnancy: maternal and fetal outcome.
Topics: Asphyxia Neonatorum; Bradycardia; Female; Fetal Growth Retardation; Fetus; Humans; Hypertension; Hyp | 1979 |
Long-term propranolol therapy in pregnancy: maternal and fetal outcome.
Topics: Asphyxia Neonatorum; Bradycardia; Female; Fetal Growth Retardation; Fetus; Humans; Hypertension; Hyp | 1979 |
Long-term propranolol therapy in pregnancy: maternal and fetal outcome.
Topics: Asphyxia Neonatorum; Bradycardia; Female; Fetal Growth Retardation; Fetus; Humans; Hypertension; Hyp | 1979 |
Long-term propranolol therapy in pregnancy: maternal and fetal outcome.
Topics: Asphyxia Neonatorum; Bradycardia; Female; Fetal Growth Retardation; Fetus; Humans; Hypertension; Hyp | 1979 |
Treatment of fetal cardiac arrhythmias.
Topics: Amiodarone; Arrhythmia, Sinus; Arrhythmias, Cardiac; Chromosome Aberrations; Chromosome Disorders; D | 1985 |